Key Market Indicator:
Ad-hoc news is mandatory information from listed companies that must be made available to investors. Depending on the occasion and content of the news, it can have an impact on the share price. The newsfeed covers a wide range of topics relevant to investor relations and is recommended as an important source of information before making an investment decision.
DE000A1MMCC8
Mon, 18.03.2024
Medios AG
Medios acquires Dutch market leader in pharmaceutical compounding services
Berlin, March 18, 2024 – Medios AG (“Medios”), the leading provider of Specialty Pharma Solutions in Germany, acquires Ceban Pharmaceuticals B.V. ("Ceban"), a fast-growing pharmaceutical compounding platform operating in the Netherlands, Belgium and Spain. With the combinat [ … ]
Tue, 22.11.2022
Medios AG
Publication of inside information pursuant to Article 17 of Regulation (EU) No. 596/2014
Acquisition of Blisterzentrum Baden-Württemberg GmbH and expansions in the area of sterile manufacturing
Berlin, November 22, 2022 – Medios AG ("Medios") today entered into a purchase agreement for the acquisition of Blisterzentrum Baden-Württemberg GmbH ( [ … ]
Tue, 22.11.2022
Medios AG
Publication of inside information pursuant to Article 17 of Regulation (EU) No. 596/2014
Acquisition of Blisterzentrum Baden-Württemberg GmbH and expansions in the area of sterile manufacturing
Berlin, November 22, 2022 – Medios AG ("Medios") today entered into a purchase agreement for the acquisition of Blisterzentrum Baden-Württemberg GmbH ( [ … ]
Thu, 03.03.2022
Medios AG
Medios AG exceeds revenue and EBT pre1 forecasts for financial year 2021 - Executive Board optimistic for financial year 2022
Berlin, March 3, 2022 - Due to stronger than expected organic growth, Medios AG ("Medios") has slightly exceeded its revenue and EBT pre1 forecasts for the financial year 2021. According to preliminary calculations (IFRS), [ … ]
Fri, 03.12.2021
Medios AG
THE INFORMATION CONTAINED IN THIS RELEASE IS NOT FOR PUBLICATION OR DISTRIBUTION IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR JAPAN OR ANY OTHER COUNTRIES WHERE SUCH DISTRIBUTION OR PUBLICATION MIGHT BE UNLAWFUL
Medios AG successfully completes capital increase with gross proceeds of approximately €72 m and placement of an upsize [ … ]
Thu, 02.12.2021
Medios AG
THE INFORMATION CONTAINED IN THIS RELEASE IS NOT FOR PUBLICATION OR DISTRIBUTION IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR JAPAN OR ANY OTHER COUNTRIES WHERE SUCH DISTRIBUTION OR PUBLICATION MIGHT BE UNLAWFUL
Medios AG resolves on capital increase against cash contributions of up to 10% of the share capital
Berlin, December 2 [ … ]
Thu, 25.11.2021
Medios AG
Medios acquires NewCo Pharma Group
Significant strengthening of market position in pharmaceutical manufacturing and significant increase in profit margins expected
Payment with cash and bank loan as well as new shares to be issued from capital increase in kind from authorized capital
Berlin, November 25, 2021 - Medios AG ("Medios") has today ent [ … ]
Thu, 26.11.2020
Medios AG
Medios AG acquires Cranach Pharma GmbH; issue of 4,180,000 new Medios shares; significant increase in sales expected in 2021 to over €1 billion
Berlin, 26 November 2020 - Medios AG ("Medios") today concluded a purchase agreement with BMSH GmbH for the acquisition of the specialized pharmaceutical wholesaler Cranach Pharma GmbH ("Cranach"), Hamburg [ … ]
Wed, 21.10.2020
Medios AG
Medios AG: Chief Executive Officer Manfred Schneider resigns from the Company's Executive Board as scheduled - Chief Financial Officer Matthias Gärtner to become the new Chief Executive Officer with early extension of his term of office
Berlin, 21 October 2020 - The Chairman of the Executive Board of Medios AG, Manfred Schneider, today informed th [ … ]
Wed, 05.08.2020
Medios AG
Medios AG adjusts forecast for 2020 financial year downward
Berlin, 5 August 2020 - Medios AG ('Medios') announces its preliminary financial figures for the first half of 2020: Group sales from January to June increased by 28.2% to €292.9 million compared to the same period of the previous year (€228.5 million), while earnings recorded a decline. [ … ]